Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/6/?d=1Neue Studien: Europe PMCdeObservation on The Formation of Neutrophil Extracellular Traps in Psoriatic Peripheral Bloodhttps://www.psoriasis-news.de/articles.html/1_articles/observation-on-the-formation-of-neutrophil-extracellular-traps-in-psoriatic-peripheral-blood-r462/Objective To explore the clinical application value of Neutrophil extracellular traps (NETs) in evaluating psoriasis. Methods 2ml peripheral blood of 63 patients with psoriasis and 27 healthy controls were collected. Neutrophils were isolated by density gradient method, and the formation of NETs was observed by immunofluorescence staining. We then calculated the proportion and fluorescence intensity of NETs and analyzed their correlation with clinical classification, severity, and serological indicators. Furthermore, the skin lesions of 5 patients with psoriasis were collected, and the NETs were observed by immunofluorescence method. Results The proportion and fluorescence intensity of spontaneous NETs in patients with psoriasis were significantly higher than those in healthy controls and were positively correlated with the PASI scores. The generation of NETs in psoriasis patients with metabolic syndrome (MetS) or high-TNF-α was higher than in psoriasis patients without metabolic abnormalities or normal-TNF-α. NETs were also observed in most psoriatic skin specimens. Conclusions The levels of NETs are correlated with the disease severity of psoriasis and patients with metabolic abnormalities and may be used as a clinical indicator to reflect the inflammatory state of psoriasis and metabolic comorbidity of psoriasis for disease evaluation.

Weiterlesen

]]>462Sun, 22 Feb 2026 17:38:20 +0000Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study.https://www.psoriasis-news.de/articles.html/1_articles/psychological-well-being-of-patients-with-moderate-to-severe-plaque-psoriasis-treated-with-tildrakizumab-28-week-interim-results-from-a-multicenter-observational-study-in-italy-using-the-dass-21-questionnaire-the-blue-study-r461/IntroductionPsoriasis is a chronic inflammatory skin disease associated with significant physical and psychological burden. Tildrakizumab, an interleukin-23 p19 inhibitor, has demonstrated efficacy in treating moderate-to-severe plaque psoriasis both in clinical trials and real-world setting. However, limited data are available on the impact of the effective treatment of psoriasis on the psychological health of patients. The aim of this study was to assess changes in psychological well-being, as well as clinical and quality-of-life outcomes, in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab in routine clinical practice in Italy.

Methods

This was an interim analysis (IA) of a 52-week multicenter, prospective, observational study. Adults with moderate-to-severe plaque psoriasis initiating tildrakizumab were enrolled. Endpoints focused on well-being and psychological health and included changes, from baseline to week 28, in Depression, Anxiety, and Stress Scale-21 (DASS-21) scores, Dermatology Life Quality Index (DLQI), European Social Survey (ESS) items, and World Health Organization-Five Well-Being Index (WHO-5). Effectiveness was also monitored via Psoriasis Area and Severity Index (PASI), and safety via treatment-emergent adverse event reporting.

Results

A total of 115 patients were included (mean age 52.5 years, 60.8% male), 102 receiving ≥ 1 dose of tildrakizumab and completing DASS-21 evaluations at baseline and week 28. At week 28, improvements were observed in DASS-21 subscales [depression (- 2.6, 95% CI - 2.0 to - 1.0), anxiety (- 2.3, 95% CI - 2.0 to - 1.0), and stress (- 3.4, 95% CI - 4.0 to - 2.0)], accompanied by marked PASI reduction (- 13.7, 95% CI - 12.8 to - 10.1). DLQI, ESS, and WHO-5 scores also improved. Adverse events were generally mild or moderate, with no unexpected safety signals.

Conclusion

In this real-world IA, tildrakizumab was observed to improve the psychological well-being of patients, reflected by a reduction in all items of the DASS-21 scale and, in parallel, confirmed its effectiveness in managing physical symptoms of psoriasis, establishing its role in the holistic management of psoriasis.

Weiterlesen

]]>461Sun, 22 Feb 2026 17:38:20 +0000Exploring the risk association between psoriasis and chronic obstructive pulmonary disease, and asthma using the NHIS database.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-risk-association-between-psoriasis-and-chronic-obstructive-pulmonary-disease-and-asthma-using-the-nhis-database-r459/BackgroundAsthma (AS) and chronic obstructive pulmonary disease (COPD) are prevalent chronic airway disorders with shared inflammatory pathways. Considering the systemic inflammatory nature of psoriasis, this study utilized the National Health Interview Survey (NHIS) to investigate its potential association with COPD and AS.

Methods

Data from the 2023 NHIS were analyzed, with participants selected based on specific inclusion criteria. A baseline table was constructed, and multivariate logistic regression models, along with risk stratification analysis, were employed to examine the correlations between psoriasis and COPD and AS. Receiver operating characteristic (ROC) analysis was conducted to assess the predictive value for both conditions.

Results

A total of 27,106 participants were included in the study. Significant differences were observed in the baseline characteristics of psoriasis, age, race, region, gender, education, marital status, employment, income, smoking habits, health status, mental health, disability, heart attack history, BMI, prediabetes, cancer, hypertension, hypercholesterolemia, arthritis, coronary heart disease, stroke, health insurance, anxiety, and depression (P < 0.001). Multivariate logistic regression revealed a strong association between psoriasis and COPD (model 1: OR 2.63, 95% CI: 2.13-3.23, P < 0.001; model 2: OR 2.43, 95% CI: 1.95-2.99, P < 0.001; model 3: OR 1.54, 95% CI: 1.21-1.96, P < 0.001). A similar association was found between psoriasis and AS (model 1: OR 1.68, 95% CI: 1.42-1.97, P < 0.001; model 2: OR 1.74, 95% CI: 1.47-2.05, P < 0.001; model 3: OR 1.32, 95% CI: 1.11-1.56, P < 0.01). The ROC analysis based on model 3 demonstrated substantial predictive power of psoriasis for COPD, with an AUC of 0.881.

Conclusion

Psoriasis was identified to have a strong association with COPD and AS, which provided valuable insights into understanding the pathogenesis of these diseases.

Weiterlesen

]]>459Sun, 22 Feb 2026 17:23:03 +0000Investigating the role of serum human beta defensin-2 in psoriasis and psoriatic arthritis: a case-control study on hBD-2 and CRP, ESR.https://www.psoriasis-news.de/articles.html/1_articles/investigating-the-role-of-serum-human-beta-defensin-2-in-psoriasis-and-psoriatic-arthritis-a-case-control-study-on-hbd-2-and-crp-esr-r458/IntroductionHuman beta-defensin 2 (hBD-2) is an antimicrobial peptide upregulated by IL-17A and TNF-α, important in skin immunity and inflammation. While hBD-2 is elevated in psoriatic skin, its systemic expression and clinical significance remain unclear, particularly in psoriatic arthritis (PsA).

Objectives

To compare serum hBD-2 levels among patients with psoriasis vulgaris, PsA, and healthy controls, and to evaluate its correlation with disease severity and inflammatory markers.

Methods

This case-control study included 66 patients with psoriasis, 30 with PsA, and 67 healthy controls. Serum hBD-2, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI). A p value < 0.05 was considered statistically significant.

Results

Median serum hBD-2 levels were significantly higher in psoriasis and PsA groups compared to controls (p < 0.001), but no significant difference was found between the two patient groups (p: 0.223). In the psoriasis group, hBD-2 showed no significant correlation with PASI (r: 0.218, p: 0.095), CRP (r: 0.158, p: 0.277), or ESR (r: 0.129, p: 0.369). CRP and ESR were significantly higher in the PsA group than in other groups (p < 0.001 and p: 0.002, respectively).

Conclusions

Although serum hBD-2 is elevated in psoriasis and PsA, it does not correlate with clinical or laboratory disease activity in psoriasis. These findings suggest that hBD-2 may reflect local cutaneous immune activation rather than systemic inflammation.

Weiterlesen

]]>458Sun, 22 Feb 2026 17:23:03 +0000Increased risk of inflammatory bowel disease in ankylosing spondylitis compared to psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/increased-risk-of-inflammatory-bowel-disease-in-ankylosing-spondylitis-compared-to-psoriasis-r457/No abstract supplied.

Weiterlesen

]]>457Sun, 22 Feb 2026 17:23:03 +0000Nail Amino Acid and Trace Element Profiles and Their Association with Clinical Severity in Nail Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/nail-amino-acid-and-trace-element-profiles-and-their-association-with-clinical-severity-in-nail-psoriasis-r456/BackgroundNail involvement is common in psoriasis, yet objective and non-invasive biomarkers of nail disease activity are limited. The biochemical composition of the nail plate may reflect local pathophysiological changes and could provide measurable indicators of disease severity.

Objective

To compare the nail biochemical composition between psoriatic patients with and without nail involvement, and to examine its associations with nail severity.

Methods

In this case-control study, nail clippings from adults with psoriasis were analyzed for trace elements (Cr, Cu, Fe, Mn, Mg, Se, Zn) by ICP-OES and for amino acids by LC-MS/MS. Group comparisons and correlation analyses with the Nail Psoriasis Severity Index (NAPSI) were conducted, and multivariable logistic regression identified independent predictors of nail involvement.

Results

Fifty-seven patients were included (30 with nail involvement; 27 without). Compared with patients without nail involvement, those with nail psoriasis showed significantly lower nail levels of several trace elements and amino acids, whereas histidine was higher (all p < 0.05). NAPSI correlated negatively with selenium, zinc, glycine, and proline, and positively with histidine. In multivariable analysis, lower nail selenium and asparagine and higher histidine independently predicted nail involvement.

Conclusion

Psoriatic nail dystrophy is associated with a distinct biochemical profile in the nail plate. Selected trace elements and amino acids correlate with clinical severity and may represent potential biochemical indicators of nail disease activity. Prospective studies are warranted to validate these findings.

Weiterlesen

]]>456Sun, 22 Feb 2026 17:23:03 +0000[Moderate-severe psoriasis and associated comorbidity in patients on biologic therapy: implications for primary care].https://www.psoriasis-news.de/articles.html/1_articles/moderate-severe-psoriasis-and-associated-comorbidity-in-patients-on-biologic-therapy-implications-for-primary-care-r455/ObjectiveTo describe the comorbidity profile in patients with moderate-to-severe psoriasis treated with biologics and their association with clinical phenotype and therapeutic choice.

Material and methods

This was an observational, cross-sectional, single-center study conducted at the Lozano Blesa University Clinical Hospital (Zaragoza, Spain). Consecutive patients with moderate-to-severe psoriasis receiving biologic treatment were included. Data were collected during the Dermatology consultation and reviewed from medical records. The variables analyzed included demographic data, clinical phenotype, previous and current treatments, cardiometabolic comorbidities, neoplasia, infections, and lifestyle habits. Statistical analysis employed means and proportions comparison tests, and logistic regression to explore associations between phenotype, comorbidities, and biologic type.

Results

350 patients were included (median age 54.1years; 57% men; 84% plaque psoriasis). The most prevalent comorbidities were dyslipidemia (55%), hypertension (42%), and obesity (36%). Among patients with liver elastography, 58% met MASLD criteria. Significant associations were observed between clinical phenotype and comorbidities: plaque psoriasis with hypertension and vitaminD deficiency, erythrodermic psoriasis with alcoholism and neoplasia, pustular psoriasis with dyslipidemia and kidney disease, and guttate psoriasis with a lower prevalence of cardiovascular factors. Guselkumab was the most commonly used biologic (15%).

Conclusions

Patients with moderate-to-severe psoriasis have a high burden of comorbidities, with differential profiles according to phenotype. These results reinforce the need for a multidisciplinary approach and the role of primary care in screening and managing comorbidities to improve disease control and overall prognosis.

Weiterlesen

]]>455Sun, 22 Feb 2026 17:23:03 +0000Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.https://www.psoriasis-news.de/articles.html/1_articles/three-year-patient-reported-outcomes-from-bimekizumab-for-plaque-psoriasis-the-be-radiant-randomized-clinical-trial-with-open-label-extension-r454/ImportancePatient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits.

Objective

To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis.

Design, setting, and participants

The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab/bimekizumab-treated patients).

Interventions

Continuous bimekizumab-treated patients received bimekizumab, 320 mg, every 4 weeks to week 16, then every 4 weeks or every 8 weeks to 1 year and into the OLE. Secukinumab/bimekizumab-treated patients received secukinumab, 300 mg, every 4 weeks to 1 year, then switched to bimekizumab, 320 mg, every 4 weeks or every 8 weeks. All received bimekizumab every 8 weeks by week 64.

Main outcomes and measures

Patient-reported itching/skin pain/scaling (Psoriasis Symptoms and Impacts Measure [P-SIM]) and concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are reported (nonresponder imputation to 1 year; modified nonresponder imputation to 1-3 years).

Results

A total of 373 bimekizumab-treated and 370 secukinumab-treated patients were randomized at baseline; 336 and 318, respectively, entered the OLE. Among bimekizumab-randomized and secukinumab-randomized patients, 127 (34.0%) and 93 (25.1%) reported no itching; 278 (74.5%) and 222 (60.0%) no skin pain; and 172 (46.1%) and 80 (21.6%) no scaling at week 4, respectively; at year 1, rates remained higher in bimekizumab-randomized vs secukinumab-randomized patients (itching: 227 [60.9%] vs 178 [48.1%]; nominal P < .001; skin pain: 293 [78.6%] vs 262 [70.8%]; nominal P = .01; scaling: 263 [70.5%] vs 184 [49.7%]; nominal P < .001). Bimekizumab-randomized patients had greater concurrent achievement rates of PASI = 0 and DLQI 0/1 vs secukinumab-randomized patients (week 4: 43 [11.5%] vs 17 [4.6%]; nominal P < .001; year 1: 230 [61.7%] vs 158 [42.7%]; nominal P < .001). In patients entering the OLE, high P-SIM = 0 rates were maintained to year 3. At OLE entry, concurrent achievement of PASI = 0 and DLQI 0/1 was reported in 69.2% continuous bimekizumab-treated and 48.5% secukinumab/bimekizumab-treated patients. After switching, secukinumab/bimekizumab responses increased, and high rates were maintained to year 3 for both continuous bimekizumab and secukinumab/bimekizumab (62.2% and 63.8%, respectively).

Conclusions and relevance

In this randomized clinical trial and OLE, bimekizumab rapidly and durably improved symptoms/health-related quality of life to 3 years, demonstrating that clinical efficacy translates to quality of life improvements. Secukinumab-randomized patients reported improvements on switching to bimekizumab.

Trial registration

ClinicalTrials.gov Identifier: NCT03536884.

Weiterlesen

]]>454Sun, 22 Feb 2026 17:23:03 +0000Guttate Psoriasis Triggered by Streptococcal Pharyngitis in Older Patients: A Case Report.https://www.psoriasis-news.de/articles.html/1_articles/guttate-psoriasis-triggered-by-streptococcal-pharyngitis-in-older-patients-a-case-report-r453/Weiterlesen

]]>453Sun, 22 Feb 2026 17:23:03 +0000Real-World Predictors of Relapse-Free Duration After Narrowband UVB in Pediatric Psoriasis: A Multicenter Study.https://www.psoriasis-news.de/articles.html/1_articles/real-world-predictors-of-relapse-free-duration-after-narrowband-uvb-in-pediatric-psoriasis-a-multicenter-study-r452/BackgroundNarrowband ultraviolet B (NB-UVB) phototherapy is a well-established, safe, and effective treatment for pediatric psoriasis; however, relapse after therapy remains a major challenge. Data regarding prognostic factors influencing remission durability in children are limited.

Objectives

To evaluate treatment response, relapse patterns, and predictors of relapse-free duration in pediatric psoriasis patients treated with NB-UVB phototherapy, with a particular focus on concomitant topical corticosteroid and calcipotriol use, and clinical features such as nail involvement.

Methods

This multicenter retrospective study included 114 pediatric psoriasis patients treated with NB-UVB across six tertiary dermatology centers in Türkiye. Treatment response was defined as ≥ 75% improvement in the Psoriasis Area and Severity Index (PASI75). Relapse was defined as clinically significant recurrence requiring renewed NB-UVB or systemic therapy within 6 months after treatment completion. Multivariable linear regression identified independent predictors of relapse-free duration.

Results

Of 114 patients (mean age 12.2 ± 3.6 years; 52.6% male), 65.8% achieved PASI75 and 42.1% PASI90. Responders received significantly higher cumulative doses and more sessions than nonresponders (p < 0.001). Relapse occurred in 24.0% of responders within 6 months. In multivariate analysis, concomitant topical corticosteroid use independently predicted longer relapse-free duration (β = 0.578, p = 0.001), whereas nail involvement predicted shorter remission (β = -0.520, p = 0.002). Topical calcipotriol and disease subtype were not significant predictors. NB-UVB was well tolerated, with mild erythema and pruritus as the most frequent adverse events (16.7%).

Conclusion

NB-UVB phototherapy provides high efficacy and an acceptable safety profile in pediatric psoriasis. Concomitant topical corticosteroid use may prolong remission, while nail involvement identifies patients at higher relapse risk, supporting closer monitoring and individualized follow-up and maintenance strategies.

Weiterlesen

]]>452Sun, 22 Feb 2026 17:23:03 +0000Macronutrient intakes and associations with psoriasis severity: a cross-sectional analysis of the asking people with psoriasis about lifestyle and eating (APPLE) study.https://www.psoriasis-news.de/articles.html/1_articles/macronutrient-intakes-and-associations-with-psoriasis-severity-a-cross-sectional-analysis-of-the-asking-people-with-psoriasis-about-lifestyle-and-eating-apple-study-r451/No abstract supplied.

Weiterlesen

]]>451Sun, 22 Feb 2026 17:23:03 +0000Sex hormone–psoriasis interactions: from sex-specific clinical features to immunoregulatory mechanismshttps://www.psoriasis-news.de/articles.html/1_articles/sex-hormonepsoriasis-interactions-from-sex-specific-clinical-features-to-immunoregulatory-mechanisms-r450/No abstract supplied.

Weiterlesen

]]>450Sun, 22 Feb 2026 17:23:03 +0000S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Hilfestellungen für besondere klinische Situationen und bei Vorliegen von Komorbiditätenhttps://www.psoriasis-news.de/articles.html/1_articles/s3%E2%80%90leitlinie-zur-therapie-der-psoriasis-vulgaris-adaptiert-von-euroguiderm-teil-2-hilfestellungen-f%C3%BCr-besondere-klinische-situationen-und-bei-vorliegen-von-komorbidit%C3%A4ten-r445/No abstract supplied.

Weiterlesen

]]>445Tue, 10 Feb 2026 08:00:25 +0000Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/real-world-efficacy-and-drug-survival-of-adalimumab-in-australian-patients-with-psoriasis-r444/BackgroundAlthough adalimumab has shown strong efficacy and safety in clinical trials, real-world evidence in Australian patients with moderate-to-severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open-label extension.

Methods

Data were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescribed adalimumab for chronic plaque psoriasis. Baseline demographics, Psoriasis Area and Severity Index (PASI) scores and treatment history between June 2006 and March 2022 were analysed. Drug survival was evaluated using Kaplan-Meier and Cox regression.

Results

A total of 306 patients were included; 59.8% had prior biologic exposure compared to 12.8% in REVEAL. The mean baseline PASI was 24.1 and at 3 months, 63.5% achieved PASI75 while 33.6% achieved PASI90. PASI90 responses remained stable through 3 years and exceeded REVEAL extension rates beyond 18 months. Median drug survival was 27.9 months; survival was 97.7%, 78.6%, 63.7% and 51.0% at 3, 9, 15 and 27 months, respectively. Male sex and achieving PASI ≤ 2 predicted longer drug survival.

Conclusions

In Australian real-world practice, adalimumab demonstrated sustained effectiveness and drug survival in patients with chronic plaque psoriasis comparable to RCTs, despite higher baseline disease severity and greater prior biologic exposure.

Weiterlesen

]]>444Tue, 10 Feb 2026 08:00:25 +0000Management of Obesity in Psoriasis Consultations.https://www.psoriasis-news.de/articles.html/1_articles/management-of-obesity-in-psoriasis-consultations-r443/IntroductionPsoriasis and obesity often occur together, with up to 50% of patients with psoriasis being classified as obese. This increases systemic inflammation, cardiovascular risk, and disease severity while reducing the efficacy of biologic treatments. Despite this overlap, dermatology lacks obesity-specific guidance. This review evaluates lifestyle, pharmacological (glucagon-like peptide 1 receptor agonists [GLP-1 RAs] and tirzepatide) and surgical strategies, as well as clinic-level algorithms, to inform dermatological practice.

Methods

We performed a narrative synthesis of epidemiology, randomized trials, real-world studies, and guideline recommendations. Our focus was on the pathophysiology and the efficacy of GLP-1 RAs and tirzepatide, providing a practical algorithm pathway for triage, pharmacotherapy escalation, and referral criteria to a multidisciplinary unit.

Results

Although there are no psoriasis-specific guidelines for obesity treatment, the strong link between the two conditions and the poorer therapeutic response observed in obese patients make addressing excess weight essential for people with psoriasis. The proposed algorithms emphasize universal lifestyle counseling and dermatology-led management for patients with a BMI (body mass index) < 35 kg/m2 and without major metabolic complications. GLP-1 RAs are considered the first-line treatment, given the available scientific evidence about their efficacy in terms of weight loss and management of comorbidities, as well as their safety profile. If weight loss with these drugs is insufficient, the next proposed treatment step is tirzepatide. Bariatric surgery, including bypass procedures, should be reserved for patients with a BMI ≥ 40 kg/m2, or with a BMI ≥ 35 kg/m2 when earlier measures have failed and/or comorbidities are not adequately controlled.

Conclusion

Dermatologists should integrate obesity assessment and patient-centered interventions into psoriasis care. A structured, multidisciplinary approach could meaningfully enhance dermatological, metabolic, and cardiovascular outcomes in patients with psoriasis and obesity.

Weiterlesen

]]>443Tue, 10 Feb 2026 08:00:25 +0000Erectile dysfunction and associated factors in males with psoriasis: a case-control study.https://www.psoriasis-news.de/articles.html/1_articles/erectile-dysfunction-and-associated-factors-in-males-with-psoriasis-a-case-control-study-r442/Weiterlesen

]]>442Tue, 10 Feb 2026 08:00:25 +0000Infliximab-induced paradoxical psoriasis successfully treated with secukinumab: A case report.https://www.psoriasis-news.de/articles.html/1_articles/infliximab-induced-paradoxical-psoriasis-successfully-treated-with-secukinumab-a-case-report-r441/Weiterlesen

]]>441Tue, 10 Feb 2026 08:00:25 +0000S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situationshttps://www.psoriasis-news.de/articles.html/1_articles/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r440/No abstract supplied.

Weiterlesen

]]>440Tue, 10 Feb 2026 08:00:25 +0000Differences in the Expression of Insulin-Like Growth Factor Signaling Pathway Members in Patients With Psoriasis Vulgaris and Controls.https://www.psoriasis-news.de/articles.html/1_articles/differences-in-the-expression-of-insulin-like-growth-factor-signaling-pathway-members-in-patients-with-psoriasis-vulgaris-and-controls-r439/Weiterlesen

]]>439Tue, 10 Feb 2026 08:00:25 +0000Advancements in psoriasis classification using custom transfer learning algorithms.https://www.psoriasis-news.de/articles.html/1_articles/advancements-in-psoriasis-classification-using-custom-transfer-learning-algorithms-r438/Weiterlesen

]]>438Tue, 10 Feb 2026 08:00:25 +0000Delayed Diagnosis of Psoriatic Arthritis Presenting with Infection-like Finger Inflammation: A Case Report.https://www.psoriasis-news.de/articles.html/1_articles/delayed-diagnosis-of-psoriatic-arthritis-presenting-with-infection-like-finger-inflammation-a-case-report-r437/Weiterlesen

]]>437Tue, 10 Feb 2026 08:00:25 +0000Single-cell transcriptomics reveals keratinocyte dynamic processes associated with S100a4 expression in psoriasiform dermatitishttps://www.psoriasis-news.de/articles.html/1_articles/single-cell-transcriptomics-reveals-keratinocyte-dynamic-processes-associated-with-s100a4-expression-in-psoriasiform-dermatitis-r436/No abstract supplied.

Weiterlesen

]]>436Tue, 10 Feb 2026 08:00:25 +0000Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity.https://www.psoriasis-news.de/articles.html/1_articles/transcriptomic-profiling-and-machine-learning-uncover-gene-signatures-of-psoriasis-endotypes-and-disease-severity-r434/BackgroundDespite increased understanding of psoriasis pathogenesis, molecular classification of clinical phenotypes and disease severity is poorly defined. Knowledge gaps include whether molecular endotypes of psoriasis underlie distinct clinical phenotypes and the positive and negative molecular regulators of disease severity across tissue compartments.

Methods

We performed comprehensive RNA sequencing of skin and blood (n = 718) from prospectively-recruited, deeply-phenotyped discovery and replication cohorts of 146 subjects with moderate-to-severe chronic plaque psoriasis initiating TNF-inhibitor (adalimumab) or IL-12/23-inhibitor (ustekinumab) therapy.

Results

Here we show, using two complementary dimensionality reduction methods, that co-expressed gene modules and factors within skin and blood are significantly associated with psoriasis phenotypes and disease severity. We identify a 14-gene signature negatively associated with BMI in nonlesional skin and with disease severity in lesional skin. Genotype integration reveals that HLA-DQA1*01 and HLA-DRB1*15 genotypes are positively associated with baseline psoriasis severity. Using explainable machine learning models, we define two disease severity-associated gene modules in lesional skin - one positive, one negatively-associated - and a 9-gene signature in lesional skin predictive of disease severity. Disease severity signatures in blood are only seen following adalimumab exposure, suggesting greater systemic impact of adalimumab compared to ustekinumab, in line with its side effect profile. In contrast, a gene signature in blood linked to HLA-C*06:02 status is independent of disease severity or drug.

Conclusions

These findings delineate gene-environmental and genetic effects on the psoriasis transcriptome linked to disease severity.

Weiterlesen

]]>434Tue, 03 Feb 2026 08:49:23 +0000Accuracy Assessment of Chinese Large Language Models in Psoriasis Management: A Multicenter Expert Consensus Studyhttps://www.psoriasis-news.de/articles.html/1_articles/accuracy-assessment-of-chinese-large-language-models-in-psoriasis-management-a-multicenter-expert-consensus-study-r433/Background Psoriasis patients in China face significant challenges due to insufficient disease knowledge and limited access to medical resources, creating a need for reliable educational tools. Objectives This multicenter consensus study aimed to systematically evaluate the consultation quality of mainstream Chinese large language models (LLMs) for psoriasis patient education. Methods "365 Questions on Psoriasis" was jointly compiled by 109 Chinese psoriasis experts. Using an expert assessment methodology, nine dermatologists curated 40 high-frequency clinical questions from the book across five domains (etiology, triggers, treatment, management, psychosocial impact). Four Chinese LLMs (DeepSeek-R1, DeepSeek-V3, GLM-4, Qwen-3) were evaluated through double-blind scoring on a 10-point Likert scale assessing accuracy, completeness, clarity, and safety. Results Performance varied significantly, with mean scores ranging from 5.95 to 9.88 (SD: 0-3.05). Qwen-3 achieved the highest average score (9.12), while GLM-4 showed the greatest inconsistency. All responses avoided dangerous content, and 87.5% proactively emphasized the necessity of consulting a physician. However, 12.5% of responses deviated from evidence-based guidelines, particularly on complex topics like biologics and management. Conclusions Chinese LLMs show substantial potential for psoriasis education by providing generally safe information and appropriately directing users to doctors. However, current limitations exist, including performance inconsistency and occasional deviations from guidelines on specialized topics, indicating they are not yet replacements for professional medical.

Weiterlesen

]]>433Tue, 03 Feb 2026 08:49:23 +0000Therapeutic approach with fatty acids in psoriasis: A systematic review.https://www.psoriasis-news.de/articles.html/1_articles/therapeutic-approach-with-fatty-acids-in-psoriasis-a-systematic-review-r432/ObjectiveThis study aims to evaluate the clinical impacts of topical and/or oral administration of compounds rich in omega-3 fatty acids from various sources, such as oils and foods, on psoriatic lesions.

Design

A systematic review was carried out.

Data sources

Searches were conducted in six databases (PubMed, Cochrane, VHL, Scopus, Embase, and Web of Science) using descriptors related to fatty acids and psoriasis.

Study selection

Inclusion criteria were studies published in the last 10 years (2013-2023) that involved patients with psoriasis and provided quantitative clinical outcome data, such as psoriasis severity scale.

Data extraction

Two independent reviewers carried out the initial screening of the titles and abstracts identified in the search. The quality of studies was evaluated using the Newcastle-Ottawa Scale, the Risk of Bias in Randomized Studies of Interventions, and the Joanna Briggs Institute critical appraisal checklist.

Results

Out of 8570 articles identified, 9 met the inclusion criteria. The quality of randomized clinical trials and observational studies varied from low to high risk of bias, according to the respective parameters of each checklist.

Conclusions

Most studies demonstrated that the topical and/or oral administration of omega-3 fatty acids from different sources significantly improved clinical parameters, as measured by severity scales and the Psoriasis Area and Severity Index (PASI).

Weiterlesen

]]>432Tue, 03 Feb 2026 08:49:23 +0000